In the Pfizer phase 3 RSV vaccine trial, three inflammatory neurologic events were initially identified within 42 days after vaccination, all in the vaccine arm: Guillain-Barré syndrome 14 days after vaccination, Miller Fisher syndrome 10 days after vaccination, and undifferentiated motor-sensory axonal polyneuropathy 21 days after vaccination.
Notes on verification
Confirmed by FDA briefing document, NEJM phase 3 trial publication, and CDC ACIP GRADE review, all independent and authoritative sources.